Stacey R Rose1, Saraschandra Vallabhajosyula2, Miguel G Velez2, Daniel P Fedorko3, Mark J VanRaden4, Juan C Gea-Banacloche5, Michail S Lionakis6. 1. Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 9000 Rockville Pike, Building 10 CRC, Room 11C 102, Bethesda, MD 20892, USA. Electronic address: Stacey.rose@nih.gov. 2. Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 9000 Rockville Pike, Building 10 CRC, Room 11C 102, Bethesda, MD 20892, USA. 3. Office of Device Evaluation, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. 4. Biostatistics Research Branch, NIAID, NIH, 6700A Rockledge Drive, Room 5135, Bethesda, MD 20817, USA. 5. Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10, Room 4B36, Bethesda, MD 20892, USA. 6. Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), 9000 Rockville Pike, Building 10 CRC, Room 11C 102, Bethesda, MD 20892, USA. Electronic address: lionakism@niaid.nih.gov.
Abstract
OBJECTIVES: To investigate the utility of beta-D-glucan (BDG) testing in bronchoalveolar lavage (BAL) fluid for the diagnosis of invasive fungal infection (IFI), as compared to BAL galactomannan (GM). METHODS: We retrospectively reviewed medical records of 132 consecutive patients at the National Institutes of Health (NIH) in whom BAL BDG testing was performed for diagnosis of pneumonia. Using the European Organization for Research and Treatment of Cancer/Mycoses Study Group guidelines, we determined which patients had proven or probable IFI, and assessed the diagnostic performance of BAL BDG testing, relative to BAL GM. We also determined the reproducibility of the BDG assay in BAL via repeat testing of patient samples. RESULTS: Ten patients had Pneumocystis pneumonia, and 34 patients had proven/probable IFI, including 14 with invasive aspergillosis (IA). BAL BDG was 100% sensitive for Pneumocystis. Although BAL BDG had similar sensitivity to BAL GM for the diagnosis of IA and IFI, it exhibited inferior specificity. Repeat testing demonstrated poor reproducibility of the BDG assay in BAL but not in serum. CONCLUSIONS: BDG testing exhibits poor specificity and reproducibility in BAL. Identification of the BAL-specific factors that may interfere with the performance of the assay could improve the clinical usefulness of BAL BDG testing. Published by Elsevier Ltd.
OBJECTIVES: To investigate the utility of beta-D-glucan (BDG) testing in bronchoalveolar lavage (BAL) fluid for the diagnosis of invasive fungal infection (IFI), as compared to BAL galactomannan (GM). METHODS: We retrospectively reviewed medical records of 132 consecutive patients at the National Institutes of Health (NIH) in whom BAL BDG testing was performed for diagnosis of pneumonia. Using the European Organization for Research and Treatment of Cancer/Mycoses Study Group guidelines, we determined which patients had proven or probable IFI, and assessed the diagnostic performance of BAL BDG testing, relative to BAL GM. We also determined the reproducibility of the BDG assay in BAL via repeat testing of patient samples. RESULTS: Ten patients had Pneumocystis pneumonia, and 34 patients had proven/probable IFI, including 14 with invasive aspergillosis (IA). BAL BDG was 100% sensitive for Pneumocystis. Although BAL BDG had similar sensitivity to BAL GM for the diagnosis of IA and IFI, it exhibited inferior specificity. Repeat testing demonstrated poor reproducibility of the BDG assay in BAL but not in serum. CONCLUSIONS:BDG testing exhibits poor specificity and reproducibility in BAL. Identification of the BAL-specific factors that may interfere with the performance of the assay could improve the clinical usefulness of BAL BDG testing. Published by Elsevier Ltd.
Authors: Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw Journal: Clin Infect Dis Date: 2008-09-01 Impact factor: 9.079
Authors: Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex Journal: Clin Infect Dis Date: 2005-07-21 Impact factor: 9.079
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Cynthia E Fisher; A Michal Stevens; Wendy Leisenring; Steven A Pergam; Michael Boeckh; Tobias M Hohl Journal: Clin Infect Dis Date: 2013-06-11 Impact factor: 9.079
Authors: Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis Journal: Transplant Cell Ther Date: 2021-03